Showing 17,381 - 17,400 results of 18,006 for search 'significantly ((((((less decrease) OR (nn decrease))) OR (teer decrease))) OR (a decrease))', query time: 0.67s Refine Results
  1. 17381

    Table 5_Isowighteone attenuates vascular calcification by targeting HSP90AA1-mediated PI3K-Akt pathway and suppressing osteogenic gene expression.xls by Yuanxi Mo (22090130)

    Published 2025
    “…(F. hispida, Moraceae), has demonstrated significant anti-inflammatory properties in prior studies. …”
  2. 17382

    Data Sheet 2_Silicon and potassium synergistically alleviate salt stress and enhance soil fertility, nutrition, and physiology of passion fruit seedlings.pdf by Alicia Camila Zeferino da Silva (22465285)

    Published 2025
    “…Foliar nutrient concentrations improved while leaf Na<sup>+</sup> decreased. Biochemically, there was a significant increase in total chlorophyll, along with reduced proline levels. …”
  3. 17383

    Table 6_Isowighteone attenuates vascular calcification by targeting HSP90AA1-mediated PI3K-Akt pathway and suppressing osteogenic gene expression.docx by Yuanxi Mo (22090130)

    Published 2025
    “…(F. hispida, Moraceae), has demonstrated significant anti-inflammatory properties in prior studies. …”
  4. 17384

    Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…</p>Results<p>Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. …”
  5. 17385

    Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…</p>Results<p>Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. …”
  6. 17386

    Table 5_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…</p>Results<p>Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. …”
  7. 17387

    Table 4_Isowighteone attenuates vascular calcification by targeting HSP90AA1-mediated PI3K-Akt pathway and suppressing osteogenic gene expression.xls by Yuanxi Mo (22090130)

    Published 2025
    “…(F. hispida, Moraceae), has demonstrated significant anti-inflammatory properties in prior studies. …”
  8. 17388

    Data Sheet 1_Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer.docx by Changde Fu (20899748)

    Published 2025
    “…</p>Results<p>The median prostate-specific antigen (PSA) was 34.1 ng/mL before neoadjuvant therapy and reduced to 0.8 ng/mL after neoadjuvant therapy (P<0.001). Testosterone showed a decreased tendency after neoadjuvant therapy, but without statistical significance (P=0.185). …”
  9. 17389
  10. 17390

    PDLB - Balance Sheet by Nguyen Linh (19516642)

    Published 2024
    “…It built out management capabilities for a much larger bank, and is currently seeing decreasing Q/Q non-interest cost, while assets and interest income are growing nicely.…”
  11. 17391

    USUV replicates in STAT1-sufficient peripheral tissues leading to spleen and liver pathology. by Amy N. Nelson (21763146)

    Published 2025
    “…<b>(G)</b> H&E staining of spleen tissue collected from mock or USUV-infected mice with a 200 µm scale bar. Decreased red pulp due to massive immune cell infiltration was observed in Vav-Cre/<i>Stat1</i><sup>fl/fl</sup> and <i>Stat1</i><sup>-/-</sup> mice. …”
  12. 17392
  13. 17393

    CDCP1 regulates CDA and hENT1 expression through c-Src/PKCδ signaling pathway. by Kun-Lin Hsieh (11401919)

    Published 2025
    “…<p>(A, B) Quantitative PCR analysis of CDA and hENT1 mRNA expression levels in T24, T24-CD, and T24-CDKO cells. …”
  14. 17394

    Table 9_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  15. 17395

    Table 1_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  16. 17396

    Table 2_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  17. 17397

    Table 10_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  18. 17398

    Table 3_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  19. 17399

    Table 8_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”
  20. 17400

    Table 6_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

    Published 2024
    “…The primary aims of this study were to estimate anti-Histoplasma antibody seroprevalence in the equid population in rural The Gambia and to explore risk factors for seropositivity.</p>Methods<p>A nationwide cross-sectional study was conducted (February–July 2022), representing baseline measurements of a longitudinal cohort study. …”